氨氯地平和依那普利联合治疗高血压病左心室舒张功能不全的疗效

目的: 研究高血压病患者左室舒张功能不全治疗的最佳方案。方法: 将60例门诊高血压病患者随机分为3组:氨氯地平组给予苯磺酸左旋氨氯地平5 mg每晚1次;依那普利组给予马来酸依那普利10 mg每日2次;联合用药组给予苯磺酸左旋氨氯地平2.5 mg每晚1次＋马来酸依那普利5 mg每日2次。对比治疗前和6个月后随访时的左室射血分数（LVEF）、心电机械图S2至E峰时间（IVRT）、二尖瓣血流峰值速度E/A,并对比各组中不良反应的发生率。结果: 3组内治疗前后LVEF无显著性差异;IVRT、E/A改善具有显著性。3组间治疗后结果比较LVEF、IVRT均无统计学差异,联合用药组E/A较单独用药组具有统计学差异（均P<0.05）。结论: 对伴有左心室舒张功能不全的高血压病患者,氨氯地平和依那普利对舒张功能的指标均有改善;而氨氯地平和依那普利小剂量联合使用,对舒张功能的指标E/A有更显著地改善,且副作用发生率较低。     

比索洛尔治疗老年高血压患者舒张性心力衰竭的疗效观察

目的观察比索洛尔(bisoprolol,商品名博苏)对老年高血压患者舒张性心力衰竭(diastolic heartfailure,DHF)的临床疗效.方法入选老年高血压患者83例,按纽约心脏协会(New YorkHeart Association,NYHA)心功能分级Ⅱ～Ⅳ级,主要表现为舒张功能不全,随机分成比索洛尔干预组42例及对照组41例,两组患者均给予抗高血压及抗心力衰竭(congestive heart failure,CHF)的常规治疗,但对照组不用β-受体阻滞剂.比索洛尔干预组患者加用比索洛尔1.25～10mg/d,疗程6个月.比较两组患者治疗前后NYH心功能分级及左室超声舒张功能指标改善情况.结果(1)比索洛尔干预组总有效率为95%;对照组总有效率为80%,两组比较有显著性差异(P＜0.05).(2)治疗前后左室等容松弛减慢指标等容舒张时间(isovolumic relaxationtime,IVRT);左室早期充盈减慢指标二尖瓣舒张早期血流最大速度E峰、舒张早期和晚期充盈速度比值(E/A)、E峰减速时间(decelerationtime,DT);以及左房前后径(Left Atrial Diameter,LAD),收缩压、舒张压、心率(heart rate,HR)等左心室舒张功能指标明显优于治疗前(P＜0.01);比索洛尔干预组IVRT、E、E/A、DT、LAD、HR等改善明显优于对照组(P＜0.01 P＜0.05).结论比索洛尔治疗老年高血压患者的舒张性心力衰竭可显著降低心率、降压,改善心功能分级和左室舒张功能.     

不同剂量比索洛尔治疗舒张性心力衰竭临床疗效的对比研究

目的比较不同剂量比索洛尔治疗舒张性心力衰竭的临床疗效。方法选取2015年3月—2017年3月临沂罗庄中心医院收治的舒张性心力衰竭患者90例,根据用药剂量分为低剂量组与高剂量组,每组45例。在常规治疗基础上,低剂量组患者予以低剂量比索洛尔治疗(1.25 mg/d),高剂量组患者予以高剂量比索洛尔治疗(5.00mg/d);两组患者均连续治疗1个月。比较两组患者治疗前后窦性心率震荡指标[震荡初始(TO)、震荡斜率(TS)]、左心室舒张末期内径(LVEDD)、室间隔厚度(IVST)、左心室后壁厚度(PWT)、舒张早期最大峰值血流速度(E值)、舒张晚期最大峰值血流速度(A值)、E/A比值,并观察两组患者治疗期间不良反应发生情况。结果治疗前两组患者TO、TS比较,差异无统计学意义(P>0.05);治疗1个月高剂量组患者TO低于低剂量组、TS高于低剂量组(P<0.05)。治疗前两组患者LVEDD、IVST、PWT、E值、A值、E/A比值比较,差异无统计学意义(P>0.05);治疗1个月高剂量组患者LVEDD、IVST、PWT小于低剂量组,E值、E/A比值高于低剂量组,A值低于低剂量组(P<0.05)。两组患者治疗期间均未发生严重不良反应。结论与低剂量比索洛尔相比,高剂量比索洛尔可更有效地改善舒张性心力衰竭患者心率及心功能,且安全性较高。     

比索洛尔和乌拉地尔逆转原发性高血压患者左心室肥厚的对比研究

目的对比研究比索洛尔和乌拉地尔逆转原发性高血压(EH)患者左心室肥厚的作用。方法将76例EH伴左心室肥厚的患者随机分为比索洛尔组和乌拉地尔组,于服药前及服药后6、12及24个月分别测定左室舒张末内径(LVDT)、舒张期室间隔厚度(IVST)、左室后壁厚度(LVPWT)、左室射血分数(LVEF)、心排血量(CO)、A峰/E峰比值(A/E比值)。结果两组治疗前后比较LVEF、CO均无变化,而A/E比值则明显降低;左室重量指数(LVMI)、左室舒张末内径(LVDd)I、VST、LVPDWT在比索洛尔组明显下降,而在乌拉地尔组则无变化。结论比索洛尔和乌拉地尔均能明显改善左室舒张功能,且比索洛尔能明显减轻左心室肥厚。     

心电图PtfV1与胸部放疗期间左室舒张功能的相关性及其临床意义

目的 探讨心电图V1导联P波终末电势（PtfV1）与胸部放疗期间左室舒张功能的相关性及其临床意义。方法 检测并比较80例胸部肿瘤患者放疗前、后的心电图PtfV1和超声心动图指标:左室舒张早期流速峰值(E)与晚期流速峰值(A)比值（E/A）、E峰减速时间（EDT）、左房内径指数（LADI）、左室射血分数（LVEF）;分析心电图PtfV1与超声检查的左室舒张功能指标的相关性;胸部放疗后将所有患者以PtfV1≤-0.03 mm·s为界值分组,统计并分析两组左室舒张功能障碍的构成比。结果 ①胸部放疗后患者PtfV1和E/A显著降低,EDT、LADI显著增加（均P<0.01）,LVEF无显著差异;②Pearson相关分析示PtfV1与EDT(r=-0.218,P<0.01)、LADI（r=-0.185,P<0.05）呈显著负相关;③多因素Logistic回归分析示PtfV1、EDT、E/A是左室舒张功能障碍的影响因素;④胸部放疗后左室舒张功能障碍构成比比较示:-0.03     

富马酸比索洛尔与卡维地洛对原发性高血压病疗效以及逆转左心室肥厚的对比研究

摘要：目的 对比研究富马酸比索洛尔和卡维地洛治疗原发性高血压（EH）的疗效以及逆转左心室肥厚的作用。方法 将106 例EH伴左心室肥厚的患者随机分为富马酸比索洛尔组和卡维地洛组,于服药前及服药后3、6 及12个月分别监测患者血压、心率并测定左室舒张末内径(LVDT)、舒张期室间隔厚度( IVST)、左室后壁厚度(LVPWT)、左室射血分数(LVEF)、心排血量(CO)、A 峰/ E 峰比值(A/ E 比值)。结果 两组治疗前后比较LVEF、CO均无变化,而A/E比值则明显降低;左室重量指数(LVMI)、左室舒张末内径(LVDd)、IVST、LVPDWT在两组均显著性降低。同期比较,富马酸比索洛尔组上述指标与卡维地洛组比较差异均有显著性意义。结论 两者均能明显改善左室舒张功能,并能明显减轻左心室肥厚。但富马酸比索洛尔组比卡维地洛减轻LVH效果更强,并可以有效控制心率。     

小剂量比索洛尔、氯沙坦治疗对左室舒张功能的影响

目的观察小剂量比索洛尔合并氯沙坦治疗6个月前后病人左室舒张功能的影响.方法 36例高血压患者(Ⅰ级20例,Ⅱ级16例)使用5 mg比索洛尔和氯沙坦50 mg,连服6个月,不改变用药量,并于治疗前后用M超和二维超声测定左室舒张功能.结果治疗6个月后血压值由168±6/99±8 mmHg降到112±7/73±9 mmHg.治疗后左室舒张功能的左室舒张早期流速峰值(PE)和舒张早期流速积分(SE)明显增高,舒张晚期流速峰值(PA)明显降低,虽舒张晚期流速积分(SA)有降低,但无显著性差别.PA/PE由0.81±0.12降至0.56±0.25(P<0.01).结论小剂量比索洛尔、氯沙坦治疗对左室舒张功能有明显改善.     

曲美他嗪对老年左室舒张功能不全患者的治疗效果

目的 探讨曲美他嗪联合常规抗心力衰竭药物治疗老年患者左室舒张功能不全的效果。方法 老年左室舒张功能不全患者97例，随机分为对照组（49例）和曲美他嗪组（48例）。观察治疗前后心率、血压、临床症状，超声检测左室射血分数（LVEF）和左室短轴缩短率（FS），左室舒张末内径（LVEDD）、左心室充盈分数（LVRFF）及二尖瓣快速充盈期/心房收缩期血流速度（E/A）的变化。 结果 治疗后两组临床症状均有改善，但曲美他嗪组明显优于对照组，曲美他嗪组显效率37%,总有效率96%(P<0.01)；治疗后两组心率、血压均无明显变化；LVEF、FS、LVEDD、LVRFF和E/A均有所增加(P<0.01)，两组间比较曲美他嗪组较对照组更为显著(P<0.05)。结论 老年左室舒张功能不全患者在常规治疗基础上加用曲美他嗪治疗，能够有效改善老年患者的左心室舒张功能，且无明显不良反应。     

比索洛尔和乌拉地尔对高血压伴左室肥大患者左室结构及功能的影响

将76例高血压病（EH）伴左室肥大的患者随机分为比索洛尔组和乌拉地尔组，于服药前及服药后6个月、12个月分别测定左室舒张末内径（LVDT）、舒张期室间隔厚度（IVST）、左室后壁厚度（LVPWT）、左室射血分数（LVEF）、心排量（CO）、A峰、E峰。结果治疗后左室重量指数（LVMI）、LVDT、IVST、LVPWT在比索洛尔组明显下降，乌拉地尔组则无变化。     

高血压病患者动态血压参数与左心室舒张功能相关

目的:探讨高血压病患者动态血压参数与左心室舒张功能的相关性。方法: 入选原发性高血压患者137例,询问病史、体检并采用超声心动图测收缩末期左、右心房内径、左心室舒张末期内径（LVEDD）、左心室射血分数（LVEF）。左心室舒张功能测定用二尖瓣舒张早期血流峰值速度/舒张晚期血流峰值速度（E/A）值,以评价左室舒张功能。根据E/A值的大小将原发性高血压患者分为两组,E/A≥1组视为左心室舒张功能正常组（n=54例）,E/A<1为左心室舒张功能不全组（n=83例）。患者均行24h动态血压及血生化检测。结果: (1)左心室舒张功能不全组的24h平均收缩压(24hSBP)、LVEDD明显高于功能正常组,差异有统计学意义(P<0.05)。（2）偏相关性分析显示左室舒张功能与LVEDD、24hSBP呈显著正相关（r值分别为0.70,0.40,P<0.01）。结论: 高血压病患者动态血压参数与左心室舒张功能相关。     

Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats

BACKGROUND: beta-blocker therapy is an established therapeutic strategy for systolic heart failure. However, its benefits in diastolic heart failure (DHF) are controversial. AIMS: This study was designed to investigate the effects of bisoprolol on DHF. METHODS AND RESULTS: Dahl salt-sensitive rats fed on 8% NaCl diet from age 6 weeks, DHF model rats, were divided into three groups at age 13 weeks. One group was treated with bisoprolol 12.5 mg/kg/day (Low dose group, n=18), one group was treated with bisoprolol 250 mg/kg/day (High dose group, n=18), and there was also an untreated group (Untreated group, n=18). The survival rate was best in the High dose group. Left ventricular hypertrophy and the expression of proinflammatory cytokines in the myocardium were significantly attenuated in the High dose group, but not in the Low dose group, and oxidative stress was most suppressed in the High dose group. Measurement with electron spin resonance revealed that bisoprolol had a potent scavenging ability, and bisoprolol attenuated the down-regulation of peroxisome proliferation-activated receptor coactivator-1alpha, an important element in the mitochondrial reactive oxygen species detoxification system. CONCLUSION: beta-blocker administration, particularly at high dose, improved the survival rate of the DHF model, at least partly through the attenuation of inflammatory changes and oxidative stress.     

比索洛尔干预高血压慢性心力衰竭左心室重构的研究

目的观察比索洛尔对老年高血压慢性心力衰竭(心衰)患者左心室重构的影响。方法选择老年高血压舒张功能不全患者98例,随机分为干预组(口服比索洛尔1.25～10 mg/d)53例和对照组45例,随访6个月。采用常规超声心动图和Tei指数检查,并进行比较分析。结果干预组治疗后左心室舒张末内径、室间隔厚度、左心室后壁厚度较治疗前明显降低(P<0.05),且优于对照组(P<0.05);干预组治疗后左心室等容松弛减慢指标、左心室早期充盈减慢指标优于治疗前(P<0.01),并优于对照组(P<0.05);干预组左心室Tei指数较治疗前显著改变(P<0.01),且优于对照组(P<0.05)。结论比索洛尔对老年高血压慢性心衰及心室重构有明显疗效、安全性好。Tei指数对综合评价心脏整体功能比常规超声心动图可能更敏感、更加合理。     

Development of different phenotypes of hypertensive heart failure: systolic versus diastolic failure in Dahl salt-sensitive rats

OBJECTIVE: There are two phenotypes of heart failure, systolic failure and isolated diastolic heart failure with preserved left ventricular systolic function. Although isolated diastolic heart failure frequently occurs, there are only models for diastolic dysfunction unassociated with heart failure and models with overt diastolic heart failure have not been established. We attempted to develop two different models, i.e. diastolic and systolic failure models, based on hypertension. MATERIALS AND METHODS: Dahl salt-sensitive rats were placed on 8% NaCl diet from 7 weeks old (7-week starting group) or 8 weeks old (8-week starting group). As an age-matched control, Dahl salt-sensitive rats were consistently placed on normal chow. In these rats, echocardiogram was serially recorded, followed by hemodynamic and histological studies. RESULTS: The 7-week starting rats showed a steep elevation in blood pressure and progressive left ventricular hypertrophy, and fell into overt heart failure at approximately 19 weeks. The development of heart failure was not associated with a decrease in left ventricular midwall fractional shortening or an increase in left ventricular end-diastolic dimension as compared with the age-matched control, which mimics the characteristics of clinically observed isolated diastolic heart failure. The 8-week starting rats showed a gradual rise in blood pressure and less progressive left ventricular hypertrophy, and fell into heart failure at approximately 26 weeks with a decrease in mid-wall fractional shortening and an increase in left ventricular end-diastolic dimension. Hemodynamic and histological studies at failing stage revealed comparable elevation of left ventricular end-diastolic pressure and comparable left ventricular fibrosis in both groups. CONCLUSION: These two different models of overt heart failure may be useful as models of isolated diastolic heart failure and systolic heart failure based on the same hypertensive heart disease, respectively, and may contribute to discrimination of the mechanisms of the development of the two different phenotypes of heart failure.     

混合高脂饲料喂养新西兰白兔建立DHF模型的实验

目的:建立兔舒张性心力衰竭(DHF)模型。方法: 采用混合高脂饲料喂养新西兰白兔12周，并设正常饲料组进行对照观察。结果: 高脂组与空白对照组比较，高脂组有心力衰竭的症状、体征，在心率、左心室收缩期最大压力上升速率(LV+dp/dtmax)、左室收缩指数（S-1）没有差异，在左室收缩压（LVSP）、左心室舒张末压(LVEDP)、左室压力最大下降速率(LV-dp/dtmax)有显著差异（P<0.05），符合DHF动物模型。结论: 采用混合高脂饲料喂养新西兰白兔可建立DHF模型。     

比索洛尔对抗β1-肾上腺素能受体自身抗体阳性心衰大鼠心功能的影响

目的 探讨比索洛尔对抗β1-肾上腺素能受体（β1-AR）自身抗体阳性心衰大鼠心功能的影响。方法 采用缩窄腹主动脉的方法,建立慢性心力衰竭的大鼠模型。将心衰组大鼠（90只最终入组65只）随机分为心衰治疗组（40只）和心衰非治疗组（25只）。心衰治疗组接受比索洛尔4周的治疗。心衰非治疗组接受同剂量的蒸馏水同样时间的治疗。应用ELISA法检测大鼠血清β1-AR自身抗体的阳性率和滴度;应用BL-420E生物机能实验系统于治疗前及治疗后4周检测心功能。结果 ①治疗组组内抗β1-AR自身抗体阳性者较阴性者左室舒张末压低,左室变化的最大速率升高,但无统计学意义;非治疗组组内抗β1-AR自身抗体阳性者较阴性大鼠的心功能进一步恶化,左室舒张末压明显升高（P<0.01）,左室变化的最大速率下降（P<0.05）。②治疗组中抗β1-AR自身抗体阳性者与非治疗组中抗β1-AR自身抗体阳性者比较,前者较后者左室舒张末压明显下降（P<0.01）;左室变化的最大速率均显著升高（P<0.05）。结论 比索洛尔治疗后,心衰大鼠抗β1-AR自身抗体阳性者的心功能较非治疗组中抗β1-AR自身抗体阳性者的心功能明显改善。同为治疗组的抗β1-AR自身抗体阳性者的心功能较阴性者的左室舒张末压低,左室变化的最大速率升高。     

Temocapril prevents transition to diastolic heart failure in rats even if initiated after appearance of LV hypertrophy and diastolic dysfunction

OBJECTIVE: Congestive heart failure with left ventricular (LV) diastolic dysfunction and preserved systolic function, i.e. diastolic heart failure (DHF), is often observed in hypertensive patients. Although angiotensin converting enzyme (ACE) inhibitors are widely used as antihypertensive therapy, there is a continued controversy about long-term effect of ACE inhibition on diastolic function. The current study was designed to elucidate a therapeutic effect of ACE inhibitor, temocapril, administration initiated after LV hypertrophy (LVH) and diastolic dysfunction are evident. METHODS: Dahl salt sensitive rats fed on 8% NaCl diet from 7 weeks (hypertensive DHF model) were studied at 13 weeks (n=6) or at 19 weeks following chronic administration of a subdepressor dose of temocapril (0.2 mg/kg/day, TEM(+), n=6) or placebo (TEM(-), n=7) from 13 weeks. RESULTS: Compensatory LVH was associated with prolonged time constant of LV relaxation (Tau) at 13 weeks. In TEM(-), progression of LVH and fibrosis and elevation of LV end diastolic pressure were observed at 19 weeks. Administration of temocapril from 13 weeks prevented the further progression of LVH and fibrosis, attenuated increases in myocardial stiffness constant and Tau, and prevented the development of DHF. These effects were accompanied with the attenuation of decreases in sarcoplasmic reticulum calcium(2+)-ATPase 2a and phosphorylated phospholamban and of hypertrophic signalings' upregulation. CONCLUSIONS: This study demonstrated that chronic administration of temocapril exerts a therapeutic effect on diastolic dysfunction and prevents the transition to DHF even if initiated after appearance of LVH and diastolic dysfunction.     

Clinical, hemodynamic and neurohumoral effects of long-term therapy of patients with severe chronic heart failure with beta-adrenoblocker bisoprolol

The use of beta-adrenoblockers in conjunction with angiotensin converting enzyme inhibitors improves quality of life and prognosis of patients with chronic heart failure. However basic mechanisms of these positive effects in severe heart failure remain to be elucidated. METHODS: Patients (n=54) with NYHA class III-IV heart failure and left ventricular ejection fraction < or =35% were randomized either to treatment with bisoprolol (1.25-10 mg/day) (n=30) or in control group (n=24) and were followed up for 12 months. RESULTS: The use of bisoprolol was associated with significant improvement of heart failure functional class, lowering of heart rate (by 14%, p<0.01), elevation of systolic blood pressure (by 7.2+/-12.3 mm Hg, p<0.01) and increase of walking distance (by 30.1+/-29.0 m, p<0.01). No significant changes of these parameters occurred in control group. After 12 months increases of left ventricular end diastolic and end systolic volumes (by 85+/-69.2 and 71+/-51.5 ml, respectively, p<0.001) and of ejection fraction (by 5.7+/-7.3%, p<0.01) took place in bisoprolol treated patients. These changes were significantly (p<0.001) higher than those in control group. After 6 months of treatment with bisoprolol noradrenaline concentration fell from 533 to 402 pg/ml (p<0.05) while in controls it rose from 369 to 474 pg/ml, p<0.01). Decreases of plasma renin activity (from 1.2 to 0.42 ng/ml/h), plasma concentrations of angiotensin II (from 17.1 to 13.1 pg/ml) and aldosterone (from 173 to 148 pg/ml, p<0.05) were also observed in bisoprolol group. No substantial dynamics of activity of main components of renin angiotensin system took place in controls. There were no significant changes of atrial natriuretic peptide in both groups. Significant positive dynamics of parameters of heart rate variability was registered only in bisoprolol group: SDNN increased by 25% (p<0.05), high frequency spectrum by 106% (p=0.03), LF/HF ratio from 2.18+/-1.41 to 1.82+/-0.7. CONCLUSION: Long term use of bisoprolol was associated with improved clinical and hemodynamic status, increased systolic BP, blocked processes of pathological left ventricular remodeling, lowered activity of not only sympathetic-adrenal but also of main components of renin-angiotensin system and improved heart rate variability.     

美托洛尔对舒张性心力衰竭兔治疗作用的研究

目的研究美托洛尔对舒张性心力衰竭兔的治疗作用。方法雄性新西兰兔30只随机分为手术组(12只,在兔右侧肾动脉上1 cm处行腹主动脉缩窄术)、治疗组(12只,从术后第1天起口服美托洛尔25mg,2次/d)和假手术组(6只,只穿线不结扎)。术后观察兔心力衰竭的临床表现,监测血流动力学变化并定期复查超声心动图。结果与手术组比较,治疗组兔心力衰竭发生率明显降低,室壁肥厚和心腔扩大得到抑制,左心室舒张末压和等容舒张期松弛时间指数以及二尖瓣舒张早期血流峰值运动速度(Em)、二尖瓣舒张早期血流峰值/Em比值显著改善(P0.05,P0.01)。结论美托洛尔可有效减轻舒张性心力衰竭兔的心室肥厚、心腔扩大和舒张功能损伤。     

Therapeutic effects of angiotensin II type 1 receptor blocker at an advanced stage of hypertensive diastolic heart failure

OBJECTIVE: Angiotensin II type 1 receptor blocker (ARB) is increasingly prescribed for the treatment of systolic heart failure with a growing body of clinical evidence. The roles of ARB, however, remain to be clarified in the treatment of diastolic heart failure (DHF), particularly at its advanced stage. This experimental study investigated the effects of ARB administered at an advanced stage of hypertensive DHF. METHODS: Dahl salt-sensitive rats fed an 8% NaCl diet from age 7 weeks represent overt DHF at age 20 weeks, as noted in previous studies (hypertensive DHF model). The DHF model rats were randomly divided into two groups at age 17 weeks when left ventricular diastolic dysfunction, hypertrophy, fibrosis, macrophage infiltration and reactive oxygen species generation were already augmented; six rats treated for 3 weeks with a subdepressor dose of ARB (olmesartan 0.6 mg/kg per day), and six untreated rats. RESULTS: The 3-week administration of ARB significantly decreased the left ventricular end-diastolic pressure in association with attenuation of left ventricular hypertrophy, fibrosis and diastolic dysfunction. Macrophage infiltration was attenuated with decreased gene expression of transforming growth factor-beta1 and monocyte chemoattractant protein-1 in the left ventricular myocardium of the ARB-treated rats. The production of reactive oxygen species also decreased with NADPH oxidase activity. CONCLUSIONS: ARB provides beneficial effects in hypertensive DHF independent of its antihypertensive effects even if initiated at an advanced stage. The beneficial effects are at least partly attributed to the attenuation of inflammatory changes and oxidative stress through the suppression of cytokine and chemokine production and of NADPH oxidase activity.     

比索洛尔对高血压病并发慢性心力衰竭患者脑钠尿肽前体的影响

目的 探讨比索洛尔对高血压病并发慢性心力衰竭（CHF）患者脑钠尿肽（BNP）前体（Pro-BNP)的影响。方法 选取我院收治的高血压病并发CHF的患者102例,随机分为试药组和对照组各51例。对照组按照高血压病并发CHF的常规治疗方案进行干预,试药组在对照组治疗方案的基础上,加用比索洛尔口服治疗。治疗3个月后对比两组患者的心功能改善情况,同时对比两组患者治疗前后的心率、血压、左室射血分数(LVEF)以及pro-BNP的变化情况。结果 试药组的显效率为49%,总有效率为96%,均显著高于对照组（分别为29%,76%,均P<0.05）;两组患者治疗后的心率、收缩压和舒张压均显著低于治疗前,而LVEF显著高于治疗前（均P<0.05）;试药组治疗后的LVEF为（44±4）%,显著高于对照组〔（35±4）%,P<0.05〕;试药组治疗后的Pro-BNP水平为（733±58） ng/L,对照组治疗后的Pro-BNP水平为（802±63） ng/L,两组患者治疗后的Pro-BNP水显著低于治疗前（均P<0.05）;试药组治疗后的Pro-BNP水平显著低于对照组（P<0.05）。结论 比索洛尔可有效降低高血压病并发CHF患者的Pro-BNP水平,提高临床疗效。